Neuroscience trials

Trials open to recruitment

AZA-PD

Parkinson’s disease (PD) is a common neurodegenerative disorder affecting approximately 2% of those over 65 years. It is characterised by problems with movement including bradykinesia, rigidity, tremor and gait dysfunction, but also causes a wide…

CCMR Two

The greatest unmet need for people with multiple sclerosis is an effective therapy for the progressive phase. Current treatments suppress the damage caused by the immune system but there is only a limited window in which these can work.…

SINAPPS2

Psychosis and schizophrenia are caused by factors associated with excess dopamine and abnormally low N-methyl D-aspartate receptor (NMDAR) functioning. There is increasing evidence for the role of inflammation in these disorders. We propose that…